{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:27:08Z","timestamp":1770236828191,"version":"3.49.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,5,1]]},"abstract":"<jats:p>Intravenous immunoglobulin (IVIG) is used to treat immune thrombocytopenia resulting from a variety of autoimmune and nonautoimmune diseases such as idiopathic thrombocytopenic purpura (ITP), heparin-induced thrombocytopenia, and posttransfusion purpura. IVIG is a limited resource and although considered safe, may nevertheless carry some risk of transferring disease. Its high cost makes monoclonal antibodies, capable of mimicking the clinical effects of IVIG, highly desirable. We show here, using a murine model of ITP, that selected monoclonal antibodies can protect against thrombocytopenia. SCID mice were pretreated with 1 of 21 monoclonal antibodies before induction of thrombocytopenia by antiplatelet antibody. Four antibodies reacted with the CD24 antigen on erythrocytes. Two antibodies were of the IgM class, and although one IgM antibody caused a minimal degree of anemia (P\u2009&lt;\u2009.05), neither antibody ameliorated immune thrombocytopenia. One of 2 anti-CD24 antibodies of the IgG class ameliorated immune thrombocytopenia and blocked reticuloendothelial system function at the same doses that protected against thrombocytopenia. Some antibodies reactive with other circulating cell types also protected against immune-mediated thrombocytopenia while no antibody without a distinct target antigen in the mice was protective. Protective monoclonal antibodies significantly prevented thrombocytopenia at down to a 1000-fold lower dose (200 \u03bcg\/kg) as compared with standard IVIG treatment (2 g\/kg). It is concluded that monoclonal IgG with specificity for a circulating cellular target antigen may provide an alternative therapeutic approach to treating immune thrombocytopenia.<\/jats:p>","DOI":"10.1182\/blood-2002-10-3078","type":"journal-article","created":{"date-parts":[[2003,4,21]],"date-time":"2003-04-21T17:30:06Z","timestamp":1050946206000},"page":"3708-3713","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":61,"title":["Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG"],"prefix":"10.1182","volume":"101","author":[{"given":"Seng","family":"Song","sequence":"first","affiliation":[{"name":"From Transfusion Medicine Research and the Department of Laboratory Medicine and Pathobiology, St Michael's Hospital, Toronto, ON; and the Canadian Blood Services and the Toronto Platelet Immunobiology Group, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Crow","sequence":"additional","affiliation":[{"name":"From Transfusion Medicine Research and the Department of Laboratory Medicine and Pathobiology, St Michael's Hospital, Toronto, ON; and the Canadian Blood Services and the Toronto Platelet Immunobiology Group, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Freedman","sequence":"additional","affiliation":[{"name":"From Transfusion Medicine Research and the Department of Laboratory Medicine and Pathobiology, St Michael's Hospital, Toronto, ON; and the Canadian Blood Services and the Toronto Platelet Immunobiology Group, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"From Transfusion Medicine Research and the Department of Laboratory Medicine and Pathobiology, St Michael's Hospital, Toronto, ON; and the Canadian Blood Services and the Toronto Platelet Immunobiology Group, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111821165681700_B1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet."},{"key":"2019111821165681700_B2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0140-6736(83)90175-7","article-title":"Effect of intravenous immunoglobulin in immune thrombocytopenia.","volume":"2","author":"Salama","year":"1983","journal-title":"Lancet."},{"key":"2019111821165681700_B3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00320381","article-title":"Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)].","volume":"49","author":"Salama","year":"1984","journal-title":"Blut."},{"key":"2019111821165681700_B4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/BF00446055","article-title":"Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D).","volume":"145","author":"Becker","year":"1986","journal-title":"Eur J Pediatr."},{"key":"2019111821165681700_B5","doi-asserted-by":"crossref","first-page":"14991502","DOI":"10.1182\/blood.V71.5.1499.bloodjournal7151499","article-title":"Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura.","volume":"71","author":"Oksenhendler","year":"1988","journal-title":"Blood."},{"key":"2019111821165681700_B6","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.V77.9.1884.1884","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect.","volume":"77","author":"Bussel","year":"1991","journal-title":"Blood."},{"key":"2019111821165681700_B7","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V89.8.2689","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.","volume":"89","author":"Scaradavou","year":"1997","journal-title":"Blood."},{"key":"2019111821165681700_B8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0955-3886(98)00043-5","article-title":"Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action.","volume":"19","author":"Lazarus","year":"1998","journal-title":"Transfus Sci."},{"key":"2019111821165681700_B9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1096-8652(199802)57:2<131::AID-AJH7>3.0.CO;2-X","article-title":"Immunologic effects of anti-D (WinRho-SD) in children with immune thrombocytopenic purpura.","volume":"57","author":"Zimmerman","year":"1998","journal-title":"Am J Hematol."},{"key":"2019111821165681700_B10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-3476(99)70367-7","article-title":"Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.","volume":"134","author":"Tarantino","year":"1999","journal-title":"J Pediatr."},{"key":"2019111821165681700_B11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0037-1963(00)90119-7","article-title":"Use of anti-D in immune thrombocytopenic purpura as a means to prevent splenectomy: case reports from 2 University Hospital Medical Centers.","volume":"37","author":"Waintraub","year":"2000","journal-title":"Semin Hematol."},{"key":"2019111821165681700_B12","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood.V78.8.2157.2157","article-title":"Anti-D Ig for treatment of immune thrombocytopenic purpura [letter].","volume":"78","author":"Bussel","year":"1991","journal-title":"Blood."},{"key":"2019111821165681700_B13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1046\/j.1537-2995.1996.36496226146.x","article-title":"Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D.","volume":"36","author":"Godeau","year":"1996","journal-title":"Transfusion."},{"key":"2019111821165681700_B14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1423-0410.1999.76402501.x","article-title":"The treatment of patients with autoimmune thrombocytopenia with intravenous IgG-anti-D.","volume":"76","author":"Engelfriet","year":"1999","journal-title":"Vox Sang."},{"key":"2019111821165681700_B15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1537-2995.1997.tb03724.x","article-title":"Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D: lack of efficiency due to absence of Fc \u03b3R-inhibiting activity [response]?","volume":"37","author":"Godeau","year":"1997","journal-title":"Transfusion."},{"key":"2019111821165681700_B16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1046\/j.1537-2995.1997.37497265347.x","article-title":"Monoclonal anti-D is not effective in the treatment of chronic autoimmune thrombocytopenic purpura [letter].","volume":"37","author":"Atrah","year":"1997","journal-title":"Transfusion."},{"key":"2019111821165681700_B17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1046\/j.1537-2995.1997.37497265348.x","article-title":"Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D: lack of efficiency due to absence of Fc \u03b3R-inhibiting activity [letter]?","volume":"37","author":"Neppert","year":"1997","journal-title":"Transfusion."},{"key":"2019111821165681700_B18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2001.03136.x","article-title":"IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.","volume":"115","author":"Crow","year":"2001","journal-title":"Br J Haematol."},{"key":"2019111821165681700_B19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science."},{"key":"2019111821165681700_B20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.V98.4.1095","article-title":"Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.","volume":"98","author":"Teeling","year":"2001","journal-title":"Blood."},{"key":"2019111821165681700_B21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group.","volume":"326","author":"van der Meche","year":"1992","journal-title":"N Engl J Med."},{"key":"2019111821165681700_B22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis.","volume":"1","author":"Gajdos","year":"1984","journal-title":"Lancet."},{"key":"2019111821165681700_B23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet."},{"key":"2019111821165681700_B24","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med."},{"key":"2019111821165681700_B25","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0140-6736(91)92797-6","article-title":"Treatment of systemic vasculitis with pooled intravenous immunoglobulin.","volume":"337","author":"Jayne","year":"1991","journal-title":"Lancet."},{"key":"2019111821165681700_B26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1076\/0927-3948(200003)811-SFT049","article-title":"Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy.","volume":"8","author":"LeHoang","year":"2000","journal-title":"Ocul Immunol Inflamm."},{"key":"2019111821165681700_B27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.V62.2.480.bloodjournal622480","article-title":"Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura.","volume":"62","author":"Bussel","year":"1983","journal-title":"Blood."},{"key":"2019111821165681700_B28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0038-1661021","article-title":"Prolongation of platelet survival in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.","volume":"51","author":"Uchida","year":"1984","journal-title":"Thromb Haemost."},{"key":"2019111821165681700_B29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2141.1999.01766.x","article-title":"Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g\/kg b.w.","volume":"107","author":"Godeau","year":"1999","journal-title":"Br J Haematol."},{"key":"2019111821165681700_B30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood.V100.3.1055","article-title":"Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response.","volume":"100","author":"Semple","year":"2002","journal-title":"Blood."},{"key":"2019111821165681700_B31","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1056\/NEJM198205273062102","article-title":"Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.","volume":"306","author":"Fehr","year":"1982","journal-title":"N Engl J Med."},{"key":"2019111821165681700_B32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.1985.tb07430.x","article-title":"Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia.","volume":"60","author":"Macintyre","year":"1985","journal-title":"Br J Haematol."},{"key":"2019111821165681700_B33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF01698483","article-title":"Immune thrombocytopenia and Fc receptor-mediated phagocyte function.","volume":"69","author":"Newland","year":"1994","journal-title":"Ann Hematol."},{"key":"2019111821165681700_B34","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-3476(84)80455-2","article-title":"Fc-depleted vs intact intravenous immunoglobulin in chronic ITP.","volume":"105","author":"Tovo","year":"1984","journal-title":"J Pediatr."},{"key":"2019111821165681700_B35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ajh.2830430119","article-title":"The infusion of anti-RhO-(D) opsonized erythrocytes may be useful in the treatment of patients, splenectomized or not, with chronic, refractory autoimmune thrombocytopenic purpura\u2014a prospective study.","volume":"43","author":"Ruiz-Arguelles","year":"1993","journal-title":"Am J Hematol."},{"key":"2019111821165681700_B36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V74.1.326.326","article-title":"High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance.","volume":"74","author":"Basta","year":"1989","journal-title":"Blood."},{"key":"2019111821165681700_B37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1365-3083.1998.00386.x","article-title":"High-dose intravenous immunoglobulin treatment activates complement in vivo.","volume":"48","author":"Mollnes","year":"1998","journal-title":"Scand J Immunol."},{"key":"2019111821165681700_B38","first-page":"679","article-title":"Complement.","volume-title":"Fundamental Immunology.","author":"Frank","year":"1989","edition":"2nd ed."},{"key":"2019111821165681700_B39","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/eji.1830231146","article-title":"Murine macrophages lack expression of the Cr2\u2013145 (CR2) and Cr2\u2013190 (CR1) gene products.","volume":"23","author":"Martin","year":"1993","journal-title":"Eur J Immunol."},{"key":"2019111821165681700_B40","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM198605083141907","article-title":"Treatment of refractory immune thrombocytopenic purpura with an anti-Fc \u03b3-receptor antibody.","volume":"314","author":"Clarkson","year":"1986","journal-title":"N Engl J Med."},{"key":"2019111821165681700_B41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1084\/jem.150.3.580","article-title":"Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.","volume":"150","author":"Unkeless","year":"1979","journal-title":"J Exp Med."},{"key":"2019111821165681700_B42","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1128\/IAI.61.11.4925-4928.1993","article-title":"An Fc \u03b3 RII-, Fc \u03b3 RIII-specific monoclonal antibody (2.4G2) decreases acute Trypanosoma cruzi infection in mice.","volume":"61","author":"Araujo-Jorge","year":"1993","journal-title":"Infect Immun."},{"key":"2019111821165681700_B43","first-page":"11","article-title":"Low dose intravenous immunoglobulin for acute immune thrombocytopenic purpura in children.","volume":"19","author":"Nuchprayoon","year":"2001","journal-title":"Asian Pac J Allergy Immunol."},{"key":"2019111821165681700_B44","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1537-2995.1994.34994378275.x","article-title":"An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia.","volume":"34","author":"Jahnke","year":"1994","journal-title":"Transfusion."},{"key":"2019111821165681700_B45","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.4049\/jimmunol.162.7.4311","article-title":"The role of the human Fc receptor Fc \u03b3 RIIA in the immune clearance of platelets: a transgenic mouse model.","volume":"162","author":"McKenzie","year":"1999","journal-title":"J Immunol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/9\/3708\/1256079\/h80903003708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/9\/3708\/1256079\/h80903003708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T18:20:50Z","timestamp":1704738050000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/9\/3708\/105815\/Monoclonal-IgG-can-ameliorate-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-10-3078","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}